We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHI
201
DELISTED
Baker Hughes
BHI
| $45.9M | 0.11% |
768,111
+18,759
| +3% | +$1.14M |
|
202
Vertex Pharmaceuticals
VRTX
$124B
| $45.8M | 0.11% |
418,521
+2,759
| +0.7% | +$243K |
|
203
Synchrony
SYF
$25.1B
| $45.4M | 0.11% |
1,324,368
+29,471
| +2% | +$1.06M |
|
204
Corning
GLW
$104B
| $45.4M | 0.11% |
1,680,828
+162,633
| +11% | +$4.33M |
|
|
205
Incyte
INCY
$25.9B
| $45.2M | 0.11% |
338,013
+139,518
| +70% | +$17.8M |
|
206
PPG Industries
PPG
$27.3B
| $45.1M | 0.11% |
429,028
+5,350
| +1% | +$542K |
|
207
Kroger
KR
$36.4B
| $44.9M | 0.1% |
1,521,740
+11,664
| +0.8% | +$373K |
|
208
Zimmer Biomet
ZBH
$18.6B
| $44.5M | 0.1% |
375,161
+8,978
| +2% | +$1.02M |
|
209
Consolidated Edison
ED
$41.7B
| $43.6M | 0.1% |
561,658
+5,960
| +1% | +$448K |
|
|
PPL
210
PPL Corp
PPL
$27.3B
| $43.6M | 0.1% |
1,165,521
+40,800
| +4% | +$1.46M |
|
211
Cardinal Health
CAH
$54.3B
| $43.2M | 0.1% |
529,893
+4,597
| +0.9% | +$362K |
|
212
Omnicom Group
OMC
$24.5B
| $43.2M | 0.1% |
500,578
+29,582
| +6% | +$2.52M |
|
213
Parker-Hannifin
PH
$125B
| $43.1M | 0.1% |
268,690
+9,910
| +4% | +$1.5M |
|
214
Paychex
PAYX
$42.3B
| $42.8M | 0.1% |
727,381
+10,788
| +2% | +$656K |
|
215
Sherwin-Williams
SHW
$88B
| $42.8M | 0.1% |
414,087
+11,856
| +3% | +$1.19M |
|
216
Baxter International
BAX
$12.5B
| $42.8M | 0.1% |
824,681
+27,700
| +3% | +$1.36M |
|
217
Rockwell Automation
ROK
$52.5B
| $42.8M | 0.1% |
274,570
+26,398
| +11% | +$3.94M |
|
218
AutoZone
AZO
$50.6B
| $42.6M | 0.1% |
58,981
+1,740
| +3% | +$1.29M |
|
|
PARA
219
DELISTED
Paramount Global Class B
PARA
| $42.6M | 0.1% |
614,520
-14,003
| -2% | -$919K |
|
220
PACCAR
PCAR
$71.8B
| $42.3M | 0.1% |
944,333
+28,638
| +3% | +$1.29M |
|
221
M&T Bank
MTB
$36.5B
| $42.1M | 0.1% |
271,828
+6,632
| +3% | +$1.07M |
|
222
Carnival Corporation Ltd
CCL
$38.8B
| $41.9M | 0.1% |
711,436
+25,332
| +4% | +$1.42M |
|
223
Roper Technologies
ROP
$38.9B
| $41M | 0.1% |
198,627
+8,224
| +4% | +$1.65M |
|
224
Clorox
CLX
$12B
| $40.3M | 0.09% |
298,964
+11,571
| +4% | +$1.5M |
|
225
Lam Research
LRCX
$338B
| $40.3M | 0.09% |
3,138,890
+86,130
| +3% | +$1.01M |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.